Analysis of buprenorphine in plasma and urine by gas chromatography

Martínez, Diego Luis Valera; Jurado, M.C.; Repetto, M.

doi:10.1016/s0378-4347(00)82404-4

Cited by 18 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, an analytical method is necessary for compliance monitoring during substitution therapy, which has been integrated in many methadone programs. A number of methods for urinary determination of buprenorphine are available, including radioimmunoassay, enzyme-linked immunosorbent immunoassay (ELISA), thin-layer chromatography, high-pressure liquid chromatography, gas chromatography (GC), gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS) (11)(12)(13)(14)(15)(16)(17)(18)(19)(20). However, automated high-volume screening tests for buprenorphine have not been available.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Buprenorphine CEDIA Assay versus GC-MS and ELISA using Urine Samples from Patients in Substitution Treatment

Böttcher¹,

Beck

2005

Journal of Analytical Toxicology

View full text Add to dashboard Cite

As buprenorphine becomes more clinically used in heroin substitution treatment, there is an increasing need for methods suitable for high-volume screening. In this study, a new immunochemical test based on CEDIA technology was evaluated for the use in clinical urine drug testing. The method was compared with an existing ELISA method and a gas chromatography-mass spectrometry (GC-MS) method on urine specimens from patients in heroin substitution treatment. The precision of the CEDIA assay was < 9% both within- and between-day at levels at and above the cutoff limit of 5 microg/L. The concordance in qualitative results with an existing ELISA method was 96.8%. The CEDIA measuring range was extended by diluting urine samples 100-fold with saline, and the results agreed well (slope of regression line was 1.09, r(2) = 0.968) with GC-MS. The sensitivity of CEDIA in detecting authentic specimen containing buprenorphine at levels >or= 5 microg/L was 99.5%. Cross-reactivity causing false-positive response was discovered in patients receiving prescribed dihydrocodeine. The urine concentration of total buprenorphine in urine from patients prescribed daily doses between 0.2 and 24 mg ranged from 0.5 to 2900 microg/L. The concentration of the metabolite norbuprenorphine was usually higher, and the median ratio of buprenorphine to norbuprenorphine was 0.23 (95% were below 1). We conclude that the CEDIA assay is suitable for application in high-volume screening of buprenorphine for urine drug testing.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Buprenorphine CEDIA Assay versus GC-MS and ELISA using Urine Samples from Patients in Substitution Treatment

Böttcher¹,

Beck

2005

Journal of Analytical Toxicology

View full text Add to dashboard Cite

show abstract

“…Because of the low concentrations and because three analytes need to be determined for pharmacokinetic study in plasma, the sensitive, accurate, precise and efficient assay was necessary for sample bioanalysis. With the GC-MS method for quantification of BUP and NBUP, the limit of quantification in plasma was only 0.1 and 2 lg mL -1 , [21][22][23], which was insufficiently sensitive to enable full pharmacokinetic profiling of BUP and NBUP and naloxone. Moody et al [24] have reported an analytical method that can simultaneously determine BUP, NBUP and naloxone using LC-MS-MS. Full validation and application were well performed in the study; however, even though BUP and NBUP were low enough to perform concentration analysis in plasma, the LLOQ of naloxone was not sensitive enough to do the pharmacokinetic profiling.…”

Section: Discussionmentioning

confidence: 99%

“…Different methods, including liquid chromatography with UV [11][12][13], fluorescence [4,14], electrochemical [15][16][17] and mass spectrometric [18][19][20] detection, have been applied to the determination of BUP and its metabolites in plasma, serum, whole blood, urine, feces, tissues, hair and sweat patches. In healthy subjects, the maximum plasma concentration (C max ) of buprenorphine and norbuprenorphine was 3.2 ng mL -1 and 0.87 ng mL -1 after a single 8 mg/2 mg dose of buprenorphine/naloxone [21]. Due to the low plasma concentrations of BUP and NBUP, a sensitive analytical method is needed for its determination in plasma.…”

Section: Introductionmentioning

confidence: 99%

“…Even though the limitation of quantification of a GC-ECD method in plasma can be 0.1 lg L -1 for BUP, NBUP and naloxone in plasma were not available for analysis with BUP in the same run using the method [22]. In the GC-MS method for quantification of BUP and NBUP, the limit of quantification in plasma was only 0.1 lg mL -1 and 2 lg mL -1 , which was insufficiently sensitive to enable full pharmacokinetic profiling of BUP and NBUP [21,23].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Simultaneous Determination of Buprenorphine, Norbuprenorphine and Naloxone in Human Plasma by LC-MS-MS

Chiang

Pao²,

Hsiong³

et al. 2011

Chromatographia

View full text Add to dashboard Cite

A novel sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS-MS) method simultaneously determined buprenorphine (BUP) and its active metabolite, norbuprenorphine (NBUP), and a coformulant, naloxone was developed, validated and applied successfully in humans. Buprenorphine-d 4 and norbuprenorphine-d 3 were used as the internal standard. The analysis was performed on a silica column, and the mobile phase was isocratic and composed of acetonitrile:2 mM ammonium formate in H2O (82:18, v/v). Mass spectrometry employed multiple reaction monitoring modes with transitions of m/z 468.1-55.2 for BUP, 414.2-101.2 for NBUP, 328.3-310.3 for naloxone, 472.1-59.2 for buprenorphine-d 4 and 417.2-101.2 for norbuprenorphine-d 3 . Lower limit of quantification (LLOQ) of the analytical method was 0.05 ng mL -1 for BUP, 0.1 ng mL -1 for NBUP and 0.025 ng mL -1 for naloxone, respectively. The standard calibration curves of BUP, NBUP and naloxone were linear over the concentration range of 0.05-20 ng mL -1 , 0.1-20 ng mL -1 and 0.025-20 ng mL -1 , respectively. The precisions (RSD) and accuracies (RE) of LLOQ and other QC samples were in acceptable range, with RSD \ 20% and RE ± 20% for LLOQ and RSD \ 15% and RE within ±15% for QC samples. The method was accurate, precise and specific, and was applied to the pharmacokinetic study of buprenorphine in healthy volunteers.

show abstract

“…The majority of them involve chromatographic procedures. Gas chromatography has been applied to its determination in plasma and urine employing N-P [4], electron-capture [4,5] and mass spectrometry [6,7] detection. The necessity of a derivatization step apart from the extraction procedure increases analysis time and the possibility of sample loss.…”

Section: Introductionmentioning

confidence: 99%

Determination of buprenorphine in biological samples by high performance liquid chromatography with electrochemical detection

2001

View full text Add to dashboard Cite

SummaryA simple, selective and rapid reversed phase high-performance liquid chromatography method with electrochemical detection is described for the analysis of buprenorphine in human serum and urine. Biological samples are easily prepared and separated on a Cls column employing acetonitrile, tetrahyclrofurane and sodium acetate as mobile phase. The composition and pH of this phase is discussed. Electrochemical detection is carried out on a glassy carbon electrode held at +0.70 V (vs. Ag/AgCI). The limit of detection is 4 x 10 -s M; the linearil',/extents belween 5 x 10 -s and 3 x 10 -6 M. High precision and recoveries were obtained. Separation from norbuprenorphine, its metabohte, is achieved in serum and urine. No interferences from the 13 substances checked were found.

show abstract

Analysis of buprenorphine in plasma and urine by gas chromatography

Cited by 18 publications

References 6 publications

Evaluation of Buprenorphine CEDIA Assay versus GC-MS and ELISA using Urine Samples from Patients in Substitution Treatment

Evaluation of Buprenorphine CEDIA Assay versus GC-MS and ELISA using Urine Samples from Patients in Substitution Treatment

Simultaneous Determination of Buprenorphine, Norbuprenorphine and Naloxone in Human Plasma by LC-MS-MS

Determination of buprenorphine in biological samples by high performance liquid chromatography with electrochemical detection

Contact Info

Product

Resources

About